PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL)

• Verfasst von: Long, Georgina [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Titel: PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL)
• Titelzusatz: a pooled analysis
• Verf.angabe: G.V. Long, J. Larkin, P.A. Ascierto, F.S. Hodi, P. Rutkowski, V. Sileni, J. Hassel, C. Lebbe, A.C. Pavlick, J. Wagstaff, D. Schadendorf, R. Dummer, D. Hogg, J.B. a. G. Haanen, P. Corrie, C. Hoeller, C. Horak, J. Wolchok, C. Robert
• Fussnoten: Gesehen am 10.11.2017
• Titel Quelle: Enthalten in: Annals of oncology
• Jahr Quelle: 2016
• Band/Heft Quelle: 27(2016,Supplement 6) Artikel-Nummer 1112PD, 1 Seite
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdw379.07
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1565243943

Abstract

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [e-mail]: NIVO + IPI and NIVO showed superior clinical activity vs IPI in a phase 3 trial of MEL patients (pts), irrespective of PD-L1 tumor expression. Among pts with high PD-L1 expression (≥5%), median progression-free survival (mPFS) was similar between NIVO + IPI and NIVO, but overall response rate (ORR) was higher with NIVO + IPI. We describe PD-L1 as a biomarker for NIVO + IPI and NIVO efficacy across phase 2 (CheckMate 069) and phase 3 (CheckMate 066 and 067) trials.Methods: Treatment-naïve pts (N = 832) with MEL received NIVO 1 mg/kg + IPI 3 mg/kg Q3W × 4 or NIVO 3 mg/kg Q2W, followed by NIVO 3 mg/kg Q2W until progression or unacceptable toxicity. Tumor tissue from primary or metastatic sites,...